GM-2505

Gilgamesh Pharmaceuticals · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	GM-2505
Sponsor	Gilgamesh Pharmaceuticals
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GM-2505 CI brief — competitive landscape report
GM-2505 updates RSS · CI watch RSS
Gilgamesh Pharmaceuticals portfolio CI